Skip to main content
Top
Published in: Lung 4/2014

01-08-2014

BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension

Authors: Yu-Xuan Feng, Dong Liu, Ming-Li Sun, Xin Jiang, Na Sun, Yi-Min Mao, Zhi-Cheng Jing

Published in: Lung | Issue 4/2014

Login to get access

Abstract

Introduction

Heterozygous germline mutations of the bone morphogenetic protein type II receptor (BMPR2) gene BMPR2 are the most important predisposing factors for heritable pulmonary arterial hypertension. BMPR2 mutation was occasionally reported in pulmonary veno-occlusive disease, appetite suppressant-related pulmonary arterial hypertension (PAH), and PAH with congenital heart disease.

Materials and Methods

In this study we identified a missense mutation (c.2296A > G) located in BMPR2 exon 12 in a patient with chronic thromboembolic pulmonary hypertension (CTEPH).

Conclusion

It is the first report of a BMPR2 mutation in CTEPH. Our study provides innovative insight into etiology of CTEPH. The genetic predisposing factor is an important component in the process of this CTEPH patient.
Literature
1.
go back to reference Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113:2011–2020CrossRefPubMed Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113:2011–2020CrossRefPubMed
2.
go back to reference Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Long-term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151–158CrossRefPubMed Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Long-term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151–158CrossRefPubMed
3.
go back to reference Runo JR, Vnencak-Jones CL, Prince M et al (2003) Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167:889–894CrossRefPubMed Runo JR, Vnencak-Jones CL, Prince M et al (2003) Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167:889–894CrossRefPubMed
4.
go back to reference Humbert M, Deng Z, Simonneau G et al (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518–523CrossRefPubMed Humbert M, Deng Z, Simonneau G et al (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518–523CrossRefPubMed
5.
go back to reference Roberts KE, McElroy JJ, Wong WP et al (2004) BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24:371–374CrossRefPubMed Roberts KE, McElroy JJ, Wong WP et al (2004) BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24:371–374CrossRefPubMed
6.
go back to reference Liu D, Liu QQ, Eyries M et al (2012) Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. Eur Respir J 39:597–603CrossRefPubMed Liu D, Liu QQ, Eyries M et al (2012) Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. Eur Respir J 39:597–603CrossRefPubMed
7.
go back to reference Pengo V, Lensing AW, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264CrossRefPubMed Pengo V, Lensing AW, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264CrossRefPubMed
8.
go back to reference Yang X, Long L, Southwood M et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053–1063CrossRefPubMed Yang X, Long L, Southwood M et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053–1063CrossRefPubMed
9.
go back to reference Rajiv DM, Nung R, Carl A et al (2003) Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 24:3277–3286 Rajiv DM, Nung R, Carl A et al (2003) Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 24:3277–3286
10.
go back to reference Joy C, Eric A, Lora H (2012) Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 126:1907–1916CrossRef Joy C, Eric A, Lora H (2012) Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 126:1907–1916CrossRef
Metadata
Title
BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension
Authors
Yu-Xuan Feng
Dong Liu
Ming-Li Sun
Xin Jiang
Na Sun
Yi-Min Mao
Zhi-Cheng Jing
Publication date
01-08-2014
Publisher
Springer US
Published in
Lung / Issue 4/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-014-9580-y

Other articles of this Issue 4/2014

Lung 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.